BioNxt Solutions Stock Price, News & Analysis (OTCMKTS:BNXTF) $0.36 -0.01 (-2.68%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.36▼$0.3650-Day Range$0.00▼$0.4352-Week Range$0.00▼$0.58Volume100 shsAverage Volume2,550 shsMarket Capitalization$38.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest About BioNxt Solutions Stock (OTCMKTS:BNXTF)BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, the United States, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.Read More BNXTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNXTF Stock News HeadlinesNovember 24, 2023 | benzinga.comBionxt Solutions Announces Convertible Debenture and Interest SettlementNovember 20, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis TreamentDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 20, 2023 | finance.yahoo.comBioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis TreamentNovember 16, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Reports on New Cladrabine ODF Product Development and Commercialization ProgramNovember 15, 2023 | finance.yahoo.comBioNxt Reports on New Cladrabine ODF Product Development and Commercialization ProgramNovember 13, 2023 | finance.yahoo.comBioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple SclerosisNovember 6, 2023 | benzinga.comBioNxt Solutions berichtet über CPHI-Kongress in BarcelonaDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 6, 2023 | finance.yahoo.comBioNxt Solutions Reports on Barcelona CPHI ConferenceOctober 27, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private PlacementOctober 27, 2023 | finance.yahoo.comBioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private PlacementOctober 3, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Solutions Announces Change of DirectorsOctober 3, 2023 | finance.yahoo.comBioNxt Solutions Announces Change of DirectorsSeptember 28, 2023 | finanznachrichten.deBioNxt Solutions Inc.: Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private PlacementSeptember 28, 2023 | finance.yahoo.comBionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private PlacementAugust 28, 2023 | finance.yahoo.comBionxt Solutions Announces Closing of First Tranche of Non-Brokered Private PlacementAugust 7, 2023 | msn.comBioNxt Solutions announces ~$4M private placementAugust 4, 2023 | finanznachrichten.deBioNxt Solutions Inc.: BioNxt Solutions Announces Non-Brokered Private PlacementAugust 2, 2023 | benzinga.comBioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative DiseaseJuly 3, 2023 | finance.yahoo.comBioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s DiseaseMay 15, 2023 | benzinga.comBioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's DiseaseMay 10, 2023 | investing.comBioNxt Solutions Inc (BNXT)May 10, 2023 | marketwatch.comBioNxt Successfully Completes Pilot Study for Contract Development CustomerApril 24, 2023 | marketwatch.comBioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical CompanyApril 18, 2023 | msn.comBioNxt buys state-of-the-art coating and cutting equipment to build out European commercial manufacturing capacityApril 17, 2023 | benzinga.comBioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing CapacitySee More Headlines Receive BNXTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNxt Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry N/A Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BNXTF CUSIPN/A CIKN/A Webwww.xphyto.com Phone780-818-6422FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,520,000.00 Net Margins-2,508.06% Pretax Margin-3,142.48% Return on EquityN/A Return on Assets-277.68% Debt Debt-to-Equity RatioN/A Current Ratio0.70 Quick Ratio0.70 Sales & Book Value Annual Sales$230,000.00 Price / Sales166.97 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-12.08Miscellaneous Outstanding Shares105,940,000Free FloatN/AMarket Cap$38.40 million OptionableNot Optionable Beta0.92 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Hugh A. D. Rogers B.Sc. (Age 43)LL.B, President, CEO & Director Comp: $175.55kMr. Patrick Joseph Meagher C.A. (Age 37)C.P.A., CA, CPA, CFO & Director Comp: $52.57kDr. Florian A. SahrHead of Project ManagementKey CompetitorsInstil BioNASDAQ:TILPrecision BioSciencesNASDAQ:DTILConcord Medical ServicesNYSE:CCMPrenetics GlobalNASDAQ:PRERapid Micro BiosystemsNASDAQ:RPIDView All Competitors BNXTF Stock Analysis - Frequently Asked Questions How have BNXTF shares performed in 2023? BioNxt Solutions' stock was trading at $0.3880 at the beginning of 2023. Since then, BNXTF stock has decreased by 6.6% and is now trading at $0.3625. View the best growth stocks for 2023 here. Are investors shorting BioNxt Solutions? BioNxt Solutions saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,800 shares, an increase of 80.0% from the October 31st total of 1,000 shares. Based on an average daily volume of 3,200 shares, the short-interest ratio is presently 0.6 days. View BioNxt Solutions' Short Interest. How do I buy shares of BioNxt Solutions? Shares of BNXTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:BNXTF) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNxt Solutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.